Mycobacterium tuberculosis: Difference between revisions

From IDWiki
Mycobacterium tuberculosis
(No difference)

Revision as of 23:19, 14 August 2019

Tuberculosis (TB)

Definition

  • Infection by Mycobacterium tuberculosis, most commonly pulmonary but can affect any organ

Classification

  • Primary vs. reactivation vs. reinfection
  • Latent vs. active

Epidemiology

  • Reinfection accounts for ~40% of active tuberculosis in endemic countries
  • Latent tuberculosis in ~30% of the global population

Presentation

  • Primary tuberculosis is usually asymptomatic
    • Possible presentations include mild URTI with cough and/or fever
    • May be seen on CXR as infiltrate in mid-lung zones with hilar adenopathy
      • Ghon complex, especially in children
    • May progress in children and the immunocompromised patients
  • Recent primary tuberculosis
    • Immunological phenomena
      • Erythema nodosum
      • Phlyctenular conjunctivitis
  • Recent or active tuberculosis
    • Erythema induratum
  • Reactivation tuberculosis
    • Poorly-defined clinical course
    • Usually reactivates in lung apices
  • Active tuberculosis
    • Cough and fever for more than two weeks
    • Cough and HIV infection
  • Extra-pulmonary tuberculosis
    • Pleural tuberculosis is most common
    • Scrofula (cervical lymph node infection) next-most common
    • Meningitis
    • Pericarditis
    • Renal
    • Abdominal
    • Gastrointestinal

Investigations

  • AM sputum for acid-fast bacilli x3
    • About 70% sensitive
  • ANTB (PCR)
    • About 75% sensitive

Management

  • Standard HREZ x2mo then HR x4mo
    • Isoniazid 5mg/kg/d, max 300mg daily
    • Rifampin 10mg/kg/d
    • Pyrazinamide 25mg/kg/d, max 2g daily
    • Ethambutol 20mg/kg/d, max 1.2g daily
    • Pyridoxine
  • Airborne precautions until:
    • Treated for at least 2 weeks
    • 3x negative sputum smears
      • Collected at 8- to 24-hour intervals, including one early morning collection
    • Improvement in symptoms

IRIS

DILI

  • Most common complication leading to treatment interruption, with a mortality of 6-12% if drugs are not stopped
  • Rif > INH > PZA
  • Most patients can have the same TB drugs reintroduced without recurrence of DILI, though recurrence can be delayed
  • Procedure
    • Hold if ALT >120 and symptoms, if ALT >200 even without symptoms, or bili >2x ULN
    • Switch to second-line meds
    • Reintroduce the original drugs once AST & ALT are <2x ULN
    • Only rechallenge with pyrazinamide if it was a mild case

Adherence to Treatment

References

  1. ^  Daphne Yee, Chantal Valiquette, Marthe Pelletier, Isabelle Parisien, Isabelle Rocher, Dick Menzies. Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis. American Journal of Respiratory and Critical Care Medicine. 2003;167(11):1472-1477. doi:10.1164/rccm.200206-626oc.
  2. ^  Jussi J. Saukkonen, David L. Cohn, Robert M. Jasmer, Steven Schenker, John A. Jereb, Charles M. Nolan, Charles A. Peloquin, Fred M. Gordin, David Nunes, Dorothy B. Strader, John Bernardo, Raman Venkataramanan, Timothy R. Sterling. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. American Journal of Respiratory and Critical Care Medicine. 2006;174(8):935-952. doi:10.1164/rccm.200510-1666st.